Johnson & Johnson to Buy Eye-Drug Maker Ollin for $2.2 Billion Upfront

The deal hands Johnson & Johnson a late-stage retinal program with its Phase 3 funding already arranged, if regulators clear the close.

Sources

Sources & evidence

What “Source checked” means

JNJLatest quote

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding a Phase 3 eye drug aimed at two leading causes of vision loss.

Johnson & Johnson said on Monday it has entered into a definitive agreement to acquire Ollin Biosciences, Inc. Ollin is a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.

The prize is OLN324, a Phase 3 investigational drug for retinal vascular diseases. It anchors a deal that also brings a separate funding pact with Blackstone Life Sciences.

The price and the close

Johnson & Johnson will pay $2.2 billion upfront for Ollin. It could pay up to approximately $1.125 billion more in regulatory and commercial milestone payments.

Together, the upfront payment and the full milestones would total $3.325 billion. That total is a TickerGrove calculation, not a figure stated in either release.

The transaction is expected to close before the end of 2026. It remains subject to applicable regulatory approvals and customary closing conditions.

Johnson & Johnson said the accounting treatment will be communicated on or before the close. No purchase-accounting detail was given in Monday's announcement.

Blackstone funds the Phase 3 program

Alongside the acquisition, Johnson & Johnson will enter a separate development funding agreement with Blackstone Life Sciences. That agreement is contingent on the acquisition closing.

Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years. The money will fully fund the Phase 3 development of OLN324.

In return, Blackstone will be eligible for certain regulatory and sales milestone payments. It will also be eligible for single-digit royalties.

What OLN324 is

OLN324 is a bispecific antibody — one antibody built to hit two targets. It is designed to target vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2).

VEGF and Ang2 are two key pathways in retinal disease. The drug is a next-generation antibody with high Ang2 potency.

Its small protein format, called a minibody, could enable improved control of retinal fluid. That fluid control is central to treating the conditions OLN324 targets.

OLN324 is being developed for wet age-related macular degeneration (AMD) and diabetic macular edema. Together, those conditions affect more than 40 million people worldwide.

Both are leading causes of vision loss. Patients with these diseases are the group directly affected if the drug succeeds.

Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, pointed to the dual targeting. "OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," Connor said.

A three-year-old company in Austin

Ollin is privately held and based in Austin, Texas. It was founded in 2023 to develop next-generation therapies in ophthalmology.

Its chief executive officer and co-founder is Jason S. Ehrlich, MD, PhD. He has led the company as it advanced OLN324 into Phase 3.

Paul Berns, a managing director at ARCH Venture Partners and Ollin's co-founder and Executive Chairman, sized the field in the release. Berns said retina therapeutics is a $15 billion worldwide market.

That market figure is Berns's statement in Ollin's release, not a TickerGrove estimate. Goldman Sachs acted as lead financial advisor to Ollin, along with Centerview Partners.

For Johnson & Johnson, the acquisition accelerates its ambition to preserve, restore and enhance vision. The company said it would strengthen its leadership in ophthalmology.

The definitive terms announced Monday replace earlier reports of talks between the companies. Those reports are superseded by the two releases and are not deal terms.

What remains unknown

Whether regulators clear the acquisition before the end of 2026 is unknown. The releases name the approvals as a condition, without a timetable.

What OLN324's Phase 3 program will show is unknown. Neither release reports Phase 3 data, a readout date, a launch plan or pricing.

How Johnson & Johnson will account for the transaction is also unknown. The company said only that the treatment will be communicated on or before the close.

Whether the milestone payments are ever earned is unknown. They depend on regulatory and commercial outcomes that have not happened.

The tests that come next

What to watch: the closing of the acquisition, expected before the end of 2026. Regulatory approvals are the gating item named in both releases.

The accounting treatment is the second test. Johnson & Johnson has promised it on or before the close.

The Phase 3 development of OLN324 is the third test. Blackstone's $750 million funding is tied to that program and starts only if the deal closes.

Sources & evidence

Source checked2 sources · 6 figures

Figure receipts

Every figure in this article, with the source it came from.

  • $2.2B Johnson & Johnson upfront payment to acquire Ollin Biosciences

    As of Nov. 16, 2026

  • $1.13B Johnson & Johnson potential milestone payments for Ollin Biosciences

    As of Nov. 16, 2026

  • $3.33B Johnson & Johnson combined potential consideration for Ollin Biosciences (TickerGrove calculation)

    As of Nov. 16, 2026

  • $750M Blackstone Life Sciences development funding for OLN324 Phase 3

    As of Nov. 16, 2026

  • 40 People worldwide affected by wet AMD and diabetic macular edema

    As of Nov. 16, 2026

  • $15B Retina therapeutics worldwide market, as stated by Paul Berns in the Ollin release

    As of Nov. 16, 2026

As of Monday, Nov. 16, 2026.

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories